Death of a Director

RNS Number : 3310A

Oncimmune Holdings PLC

06 June 2016

 

PRESS RELEASE                                                                                              6 June 2016

Oncimmune Holdings plc (the "Company")

Death of a Director

Nottingham, UK - 6 June 2016: Oncimmune Holdings plc (AIM: ONC.L) sadly announces the death of Robert (Bob) Page, the Company's CFO and a director who died unexpectedly on Friday 3 June 2016 from natural causes.

The Company's sympathies are with his family.

All of his responsibilities have been assumed by other members of staff for an interim period, including Andrew Millet, BA MBA, FCA, the current Company Secretary and a practising chartered accountant, who will take the role of interim CFO. The Company has started the process to recruit a new CFO.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Andrew Jones, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 140,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit www.oncimmune.com

 

END

 

 

BOAEADKKEFAKEFF